Denosumab is a fully human monoclonal antibody for the treatment of osteoporosis, treatment induced bone loss, bone metastases, rheumatoid arthritis, multiple myeloma and giant cell tumor of bone. Denosumab is designed to target RANKL (RANK ligand), a protein that acts as the primary signal to promote bone removal. In many bone loss conditions, RANKL overwhelms Read More →

Denosumab is a RANK ligand (RANKL) inhibitor indicated for:  Treatment of postmenopausal women with osteoporosis at high risk for fracture Mechanism of action: Denosumab binds to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption.  Denosumab prevents RANKL from activating its receptor, RANK, Read More →